Patent ID: 6630513
Filing Date: 2003-10-07
Classification: A61K,C07C,C07D,C07K

Abstract:
A method of treating human cervical adenocarcinoma, which method comprises administering to a mammalian subject in need thereof a therapeutically effective amount of a composition comprising a compound of formula: or a pharmaceutically acceptable salt thereof, whereinY is a linear or cyclic peptide having from four to fourteen amino acid residues, or a radical of formula -Aa-Z, wherein Aa is an amino acid or dipeptide residue and Z is a member selected from the group consisting of hydrogen, â€”CHO, whereinR5, R6 and R7 are each independently selected from the group consisting of hydrogen, (C1-C8)alkyl, (C1-C8)heteroalkyl, aryl, heteroaryl, aryl(C1-C4)alkyl, aryl(C1-C4)heteroalkyl, heteroaryl(C1-C4)alkyl and heteroaryl(C1-C4)heteroalkyl, and R5 and R6 are optionally linked together to form a 5- or 6-membered ring; R8 is a member selected from the group consisting of (C1-C8)alkyl, (C1-C8)heteroalkyl, aryl(C1-C4)alkyl and aryl(C1-C4)heteroalkyl; R9 and R10 are members independently selected from the group consisting of hydrogen, (C1-C8)alkyl, (C1-C8)heteroalkyl, aryl(C1-C4)alkyl and aryl(C1-C4)heteroalkyl, and are optionally linked together to form a 5- or 6-membered ring; R1 and R4 are each members independently selected from the group consisting of hydrogen, (C1-C6)alkyl and (C1-C6)heteroalkyl; R2 and R3 are each independently selected from the group consisting of hydrogen, halogen, (C1-C8)alkyl, (C1-C8)heteroalkyl, â€”OR11, â€”SR11 and â€”NR11R12, wherein R11 and R12 are each independently selected from the group consisting of hydrogen, (C1-C8)alkyl and (C1-C8)heteroalkyl; and R2 and R3, when attached to adjacent carbon atoms, are optionally linked together to form a fused 5-, 6- or 7-membered ring; and Ar is a substituted aryl group selected from the group consisting of: whereinX1 and X2 are each independently selected from the group consisting of F, Cl and Br.